...
首页> 外文期刊>Asian Journal of Pharmaceutical and Clinical Research >COMPARATIVE STUDY OF THE ORIGINAL TECHNOLOGY OF MICRONIZATION OF THE PURIFIED FLAVONOID FRACTION OF “DETRALEX?” AND THE TECHNOLOGY OF MICRONIZATION OF DRUGS D AND N OF THE UKRAINIAN MANUFACTURERS
【24h】

COMPARATIVE STUDY OF THE ORIGINAL TECHNOLOGY OF MICRONIZATION OF THE PURIFIED FLAVONOID FRACTION OF “DETRALEX?” AND THE TECHNOLOGY OF MICRONIZATION OF DRUGS D AND N OF THE UKRAINIAN MANUFACTURERS

机译:微粉化“ Detralex?”纯化黄酮成分的原始技术的比较研究和乌克兰制造商的药物D和N的微粉化技术

获取原文
           

摘要

Objective: The objective of the study was to compare the degree of micronization of the bioflavonoid fraction (90% diosmin and 10% hesperidin) of different manufacturers which used for the treatment of the chronic venous insufficiency. Methods: “Detralex?,” medicines N and D, 500 mg coated tablets each were used as studied objects. Microscopy of the tablets matrix of the investigational drugs was performed after spontaneous decomposition in a water solution at pH=6.8, using a modular light field microscope of the research class B-1000BF (Optika, Italy) with a digital camera Optikam HDMI Pro (Optika, Italy) with measuring of the size of the flavonoid fraction granules. Results : About 92.8% of the granules of the “Detralex?” tablets matrix were presented by the smallest size of the granules (1–5 μ), unlike D and N, in which 12.9% and 10% of the same size granules were observed. Giant granule size (up to 50 μm) was discovered in D and N tablets matrix and no such granules size were found in the “Detralex?” tablets matrix. Conclusion: Different degrees of micronization of the purified flavonoid fraction in the studied test samples indicate that the drugs D and N are not pharmaceutically equivalent to the original “Detralex?” drug and cannot be considered as copies without further research.
机译:目的:本研究的目的是比较用于治疗慢性静脉功能不全的不同制造商的生物类黄酮成分(90%的薯os和10%的橙皮苷)的微粉化程度。方法:将“ Detralex”,N和D药物,每片500毫克的包衣片剂用作研究对象。使用研究级B-1000BF(意大利Optika)的模块化光场显微镜和数码相机Optikam HDMI Pro(Optika),在pH = 6.8的水溶液中自发分解后,对研究药物的片剂基质进行显微镜检查,意大利)中测量类黄酮部分颗粒的大小。结果:“ Detralex?”颗粒约占92.8%不同于D和N,其中最小粒径的颗粒(1-5μ)代表了片剂基质,其中D和N的粒径分别为12.9%和10%。在D和N片剂基质中发现了巨大的颗粒大小(最大50μm),在“ Detralex?”中没有发现这样的颗粒大小片矩阵。结论:研究样品中纯化的类黄酮组分的微粉化程度不同,表明药物D和N在药物上不等同于原始的“ Detralex?”。药物,未经进一步研究就不能视为复制品。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号